Tag: FDA exclusivity
Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market
Biosimilars in the U.S. face a 12-year exclusivity period before approval, delayed further by patent litigation and complex development costs. Unlike generics, they require massive investment and regulatory hurdles, leaving patients paying higher prices for years.
Categories
- Medications (64)
- Health and Wellness (46)
- Pharmacy Services (12)
- Chronic Conditions (7)
- Women Health (6)
- Health and Nutrition (5)
- Medical Research (3)
- Mental Health (3)
- Skincare (2)
- Men Health (2)
